Skip To Main Content

Inspiration and Innovation

Get inspired and stay on the cutting edge of innovation with these resources.

Sort by

Filters

Reset
  • Therapeutical Areas
  • Type of Content
VTE Safety Zone 2023 Program Highlights

VTE Safety Zone 2023 Program Highlights

Single-Pill Combinations in Dyslipidemia

Single-Pill Combinations in Dyslipidemia

This review describes the potential benefits of combination treatment and presents data supporting the use of single-pill combination (SPC) for increasing exposure to lipid-lowering treatment (LLT).

Managing Recurrent ASCVD risk of your ACS Patient: A call to Action – GULF Perspective: Part 2

Managing Recurrent ASCVD risk of your ACS Patient: A call to Action – GULF Perspective: Part 2

Should we encourage earlier and broader use of combination therapies in dyslipidemia?

Should we encourage earlier and broader use of combination therapies in dyslipidemia?

Possible Challenges Post One Year of ESC/EAS Guidelines

Possible Challenges Post One Year of ESC/EAS Guidelines

The ROSETTE Study

The ROSETTE Study

Fabry

Fabry

About MRD

About MRD

Minimal Residual Disease

Minimal Residual Disease

Look beyond the symptoms to identify and manage Patients with Type 2 Inflammation

Look beyond the symptoms to identify and manage Patients with Type 2 Inflammation

Changing trends in VTE: Pulmonary Embolism cases on Rise within the Last Decade

Changing trends in VTE: Pulmonary Embolism cases on Rise within the Last Decade

Danish study finds more elderly and patients with comorbidities being diagnosed.

PCSK9i after hospital discharge for acute MI

PCSK9i after hospital discharge for acute MI